Makcin 500 mg filmom obložene tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

makcin 500 mg filmom obložene tablete

belupo lijekovi i kozmetika d.d., ulica danica 5, koprivnica, hrvatska - klaritromicin - filmom obložena tableta - 500 mg - urbroj: jedna filmom obložena tableta sadrži 500 mg klaritromicina

Makcin SR 500 mg tablete s produljenim oslobađanjem Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

makcin sr 500 mg tablete s produljenim oslobađanjem

belupo lijekovi i kozmetika d.d., ulica danica 5, koprivnica, hrvatska - klaritromicin - tableta s produljenim oslobađanjem - 500 mg - urbroj: jedna tableta s produljenim oslobađanjem sadrži 500 mg klaritromicina

Xenleta Europska Unija - hrvatski - EMA (European Medicines Agency)

xenleta

nabriva therapeutics ireland dac - lefamulin acetate - pneumonia, bacterial; community-acquired infections - antibakterijski lijekovi za sistemsku primjenu, - xenleta is indicated for the treatment of community-acquired pneumonia (cap) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of cap or when these have failed. treba uzeti u obzir formalne preporuke za odgovarajuće korištenje antibakterijskih posrednika.

Tukysa Europska Unija - hrvatski - EMA (European Medicines Agency)

tukysa

seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - antineoplastična sredstva - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.

Brukinsa Europska Unija - hrvatski - EMA (European Medicines Agency)

brukinsa

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastična sredstva - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).